Contrave
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $27.34 | 2 | 2 |
| 2018 | $109.61 | 8 | 8 |
| 2017 | $16,120 | 12 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,750 | 5 | 90.7% |
| Consulting Fee | $975.00 | 1 | 6.0% |
| Food and Beverage | $532.44 | 16 | 3.3% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A multicenter, randomized, double-blind, placebo-controlled, Phase 4 study to assess the effect of naltrexone hydrochloride and bupropion hydrochloride extended release combination on the occurrence of major adverse cardiovascular events | Takeda Development Center Americas, Inc. | $14,750 | 0 |
Top Doctors Receiving Payments for Contrave
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Saratoga Springs, NY | $14,750 | 5 |
| , M.D | Endocrinology, Diabetes & Metabolism | Orlando, FL | $975.00 | 1 |
| , M.D | Internal Medicine | Bolingbrook, IL | $119.92 | 1 |
| , MD | Internal Medicine | Bolingbrook, IL | $119.92 | 1 |
| , M.D | Internal Medicine | Plainfield, IL | $119.92 | 1 |
| , DO | Internal Medicine | Pittsburgh, PA | $19.10 | 1 |
| , MD | Internal Medicine | Tulsa, OK | $13.67 | 1 |
| , M.D | Internal Medicine | Tulsa, OK | $13.67 | 1 |
| , M.D | Family Medicine | Gowanda, NY | $13.08 | 1 |
| , MD | Internal Medicine | Memphis, TN | $13.02 | 1 |
| , MD | Internal Medicine | Memphis, TN | $13.02 | 1 |
| , MD | Internal Medicine | Memphis, TN | $13.02 | 1 |
| , MD | Internal Medicine | Memphis, TN | $13.02 | 1 |
| , MD | Internal Medicine | Memphis, TN | $13.02 | 1 |
| , D.O | Emergency Medicine | Senatobia, MS | $12.33 | 1 |
| , DO | Family Medicine | Fresno, CA | $11.91 | 1 |
| , D.O | Adult Medicine | Fresno, CA | $11.91 | 1 |
| , M.D | Obstetrics & Gynecology | Clovis, CA | $11.91 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $16,257
- Total Doctors 17
- Transactions 22
About Contrave
Contrave is a drug associated with $16,257 in payments to 17 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Development Center Americas, Inc..
Payment data is available from 2017 to 2019. In 2019, $27.34 was paid across 2 transactions to 2 doctors.
The most common payment nature for Contrave is "Unspecified" ($14,750, 90.7% of total).
Contrave is associated with 1 research study, including "A multicenter, randomized, double-blind, placebo-controlled, Phase 4 study to assess the effect of naltrexone hydrochloride and bupropion hydrochloride extended release combination on the occurrence of major adverse cardiovascular events" ($14,750).